Swiss National Bank increased its stake in Mylan (NASDAQ:MYL) by 0.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,680,542 shares of the company’s stock after purchasing an additional 3,000 shares during the quarter. Swiss National Bank’s holdings in Mylan were worth $71,104,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Pzena Investment Management LLC raised its holdings in shares of Mylan by 84.1% in the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after purchasing an additional 10,381,697 shares during the period. Greenlight Capital Inc. raised its holdings in shares of Mylan by 0.4% in the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after purchasing an additional 42,600 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Mylan by 6.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 4,095,700 shares of the company’s stock worth $128,481,000 after purchasing an additional 232,762 shares during the period. Orbimed Advisors LLC raised its holdings in shares of Mylan by 20.9% in the 3rd quarter. Orbimed Advisors LLC now owns 3,601,100 shares of the company’s stock worth $112,967,000 after purchasing an additional 621,900 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Mylan by 20.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 3,553,480 shares of the company’s stock worth $111,450,000 after purchasing an additional 612,513 shares during the period. 75.56% of the stock is currently owned by institutional investors.

MYL has been the topic of a number of analyst reports. Royal Bank of Canada set a $32.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Friday, October 20th. Mizuho reissued a “buy” rating and set a $37.00 target price on shares of Mylan in a report on Tuesday, October 24th. BidaskClub raised shares of Mylan from a “hold” rating to a “buy” rating in a report on Friday, October 27th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan and gave the company a “hold” rating in a report on Tuesday, October 31st. Finally, Zacks Investment Research cut shares of Mylan from a “buy” rating to a “hold” rating in a report on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and thirteen have issued a buy rating to the company. Mylan has an average rating of “Buy” and an average target price of $44.65.

Mylan (NASDAQ:MYL) opened at $41.34 on Thursday. The company has a market cap of $21,677.39, a price-to-earnings ratio of 8.60, a PEG ratio of 1.09 and a beta of 1.35. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 1 year low of $29.39 and a 1 year high of $47.82.

In other news, CEO Heather M. Bresch sold 75,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.69% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2018/02/15/mylan-myl-shares-bought-by-swiss-national-bank.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan (NASDAQ:MYL).

Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.